Past studies have demonstrated reduced glial-mediated neuroinflammation with pharmacological Fyn inhibition in kainic acid (KA)-induced epilepsy (Sharma et al., 2018), AD or tauopathy (Kaufman et al., 2015; Tang et al., 2020), and Parkinson's disease (Panicker et al., 2019) models. Here, FYN is linked to Alzheimer disease.